Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.
作者信息
Smith Timothy R, Spierings Egilius L H, Cady Roger, Hirman Joe, Schaeffler Barbara, Shen Vivienne, Sperling Bjørn, Brevig Thomas, Josiassen Mette Krog, Brunner Elizabeth, Honeywell Loan, Mehta Lahar
机构信息
StudyMetrix Research, LLC, 3862 Mexico Road, St. Peters, MO, 63303, USA.
Medvadis Research Corporation, Boston PainCare, Waltham, MA, USA.
出版信息
J Headache Pain. 2021 May 25;22(1):46. doi: 10.1186/s10194-021-01253-3.
Abstract
摘要
相似文献
1
Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.对《eptinezumab治疗偏头痛患者的安全性和耐受性：5项临床试验的汇总分析》的更正
J Headache Pain. 2021 May 25;22(1):46. doi: 10.1186/s10194-021-01253-3.
2
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.依替唑仑单抗治疗偏头痛患者的安全性和耐受性：5 项临床试验的汇总分析。
J Headache Pain. 2021 Mar 30;22(1):16. doi: 10.1186/s10194-021-01227-5.
3
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.依普替扎umab 预防偏头痛的安全性和疗效在有两到四次先前预防治疗失败的患者中（DELIVER）：一项多臂、随机、双盲、安慰剂对照、3b 期试验。
Lancet Neurol. 2022 Jul;21(7):597-607. doi: 10.1016/S1474-4422(22)00185-5.
4
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.依替唑仑单抗治疗慢性偏头痛合并药物过度使用性头痛双重诊断患者的疗效、耐受性和安全性：PROMISE-2 的亚组分析。
Headache. 2021 Jan;61(1):125-136. doi: 10.1111/head.14036. Epub 2020 Dec 13.
5
Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine.依替巴肽单抗的临床免疫原性评估，依替巴肽单抗是一种针对降钙素基因相关肽（CGRP）的治疗性人源化单克隆抗体，用于偏头痛的预防性治疗。
Front Immunol. 2021 Oct 25;12:765822. doi: 10.3389/fimmu.2021.765822. eCollection 2021.
6
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2.依替唑仑单抗治疗有先兆偏头痛患者的疗效和安全性：PROMISE-1 和 PROMISE-2 的事后分析。
Cephalalgia. 2022 Jul;42(8):696-704. doi: 10.1177/03331024221077646. Epub 2022 Mar 18.
7
Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE-The First Italian Multicenter, Prospective, Real-Life Study.评估依替奈单抗在真实世界中治疗高频和慢性偏头痛的有效性、耐受性及安全性：EMBRACE——意大利首个多中心、前瞻性、真实世界研究
Brain Sci. 2024 Jun 30;14(7):672. doi: 10.3390/brainsci14070672.
8
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies.预防偏头痛用依替巴肽治疗成年人的心血管结局：四项随机、双盲、安慰剂对照研究的汇总数据。
J Headache Pain. 2021 Nov 25;22(1):143. doi: 10.1186/s10194-021-01360-1.
9
Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review.艾普替奈umab用于发作性和慢性偏头痛的预防性治疗：一项叙述性综述
Front Neurol. 2024 Mar 8;15:1355877. doi: 10.3389/fneur.2024.1355877. eCollection 2024.
10
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.依替唑仑单抗预防慢性偏头痛：一项随机 2b 期临床试验。
Cephalalgia. 2019 Aug;39(9):1075-1085. doi: 10.1177/0333102419858355. Epub 2019 Jun 24.
引用本文的文献
1
Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab.偏头痛预防性单克隆抗体的上市后安全性：基于EudraVigilance数据库对eptinezumab、fremanezumab、galcanezumab和erenumab的分析。
Headache. 2025 Jul-Aug;65(7):1080-1094. doi: 10.1111/head.14962. Epub 2025 May 29.
本文引用的文献
1
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.依替唑仑单抗治疗偏头痛患者的安全性和耐受性：5 项临床试验的汇总分析。
J Headache Pain. 2021 Mar 30;22(1):16. doi: 10.1186/s10194-021-01227-5.
Zotero 插件